New: Our latest case study on qFibrosis' role in the successful development of Rezdiffra


HistoIndex Charts New Course in Liver Disease Innovation: Announces Pivotal Changes to Scientific Advisory Board

Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress

HistoIndex to Showcase Groundbreaking AI-powered Stain-free Digital Pathology Advances with 8 Accepted Abstracts at EASL Congress 2024

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Histoindex’s tissue imaging tech demonstrates consistent results in measuring fibrosis

How AI is shaping clinical research and trials

Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™

HistoIndex Presents Advancements in AI-powered Stain-free Tissue Imaging for NASH Clinical Trials at EASL Congress 2023

TANDEM study shows potential of HistoIndex SHG/TPE imaging and AI-based technology in evaluating the effects of combination therapy for NASH

HistoIndex SHG/TPE imaging and AI-based technology reveals dose-dependent effectiveness of Tropifexor for NASH patients in Nature Medicine

HistoIndex embarks on partnership with VCU’s Stravitz-Sanyal Institute for Liver Disease and Metabolic Health in the study of liver diseases

Appointment of Dr. David John Jeans CBE as HistoIndex’s Non-Executive Chairman

HistoIndex Stain-free AI-DP Reveals Treatment-induced Zonal Regression of Fibrosis Colocalized with Reduction in Steatosis & Hepatocyte Ballooning in FLIGHT-FXR NASH Clinical Trial

HistoIndex and Global Liver Experts Advance Stain-free AI Quantification of Hepatocyte Ballooning as a Reproducible Approach and Potential Endpoint for NASH Clinical Trials

HistoIndex and Galecto to Collaborate on Galecto’s Phase 2a MYLOX-1 Clinical Trial to Advance Myelofibrosis Assessment with AI-based Stain-free Digital Pathology

HistoIndex’s Stain-free AI-based Digital Pathology Incorporated as Secondary and Exploratory Efficacy Endpoints in Sagimet’s NASH FASCINATE-2 Phase 2b Clinical Trial

HistoIndex’s AI-Based Digital Pathology Indicates Concomitant Histological Improvements in Liver Fat and Fibrosis in Nonalcoholic Steatohepatitis (NASH) Patients Treated with Tropifexor Compared with Placebo

Singapore: A Myriad of Biotech Financing Strategies

A proprietary biophotonics technology and platform for stain-free AI-based digital pathology

HistoIndex Explores the Clinical Utility of Stain-free AI Digital Pathology Platform in 388 Patients with Triple-Negative Breast Cancer (TNBC)

Behind the Success of Singapore’s Healthcare and Biomedical Startups

HistoIndex’s AI-based Digital Pathology Platform: A Validated Quantification Tool Recommended in the Guidelines for the Prevention and Treatment of Chronic Hepatitis B in China

qFIBS Demonstrates Suitability for Nonalcoholic Steatohepatitis (NASH) Assessment in Clinical Trials and Patient Care with Full Quantification of All Histopathological Features

HistoIndex Announces Global Partnerships to Expand AI-Based Digital Pathology Platform as a Drug Discovery Tool in Preclinical Studies for Nonalcoholic Steatohepatitis (NASH)

LITMUS – Progress towards diagnosing and better treating liver disease

HistoIndex and ILBS Launch Centre of Excellence in New Delhi for Advanced Diagnostics and Clinical Research on Nonalcoholic Steatohepatitis (NASH)

SGH develops test that achieves consistency, accuracy in measuring the extent of fatty liver

HistoIndex’s Second Harmonic Generation (SHG) Technology: A Potentially Important Tool Used In Madrigal’s Phase 2 Nonalcoholic Steatohepatitis (NASH) Clinical Trial

Southeast Asia’s largest medical device maker ready to fund ‘category disruptor’ start-ups

A Worldwide Effort to Defeat Nonalcoholic Steatohepatitis (NASH)

HistoIndex and CymaBay Therapeutics Team Up to Advance NASH Drug Development

Forging New Paths In Cancer Diagnostics

A more accurate way to diagnose liver diseases

HistoIndex Receives Frost & Sullivan 2017 Asia-Pacific Best Practices Award for Innovative Diagnostics in the Area of Nonalcoholic Steatohepatitis (NASH)

Exposing A Silent Killer: Liver Disease

Building ties in pharma industry ‘just like courtship’

Beautiful Science

Leading The Disruption Of Tissue Imaging

Zicom Group invests in Singapore growth phase medtech Histoindex

HistoIndex sets new standards in fibrosis diagnosis